Investing Experience -
Risk Profile -
Followers
0
Following
0
Blog Posts
0
Threads
2,267
Blogs
Threads
Portfolio
Follower
Following
Summary
Total comments
2,267
Past 30 days
0
Past 7 days
0
Today
0
User Comments
Stock
2021-06-26 00:58 | Report Abuse
KUALA LUMPUR (Bernama) -- My E.G. Services Bhd has signed a letter of intent (LOI) to purchase 10 million doses of Anhui Zhifei Biopharmaceutical Co Ltd’s COVID-19 vaccine, ensuring that the corresponding quantity of its recombinant protein subunit vaccine is reserved for delivery as early as August.
In a filing with Bursa Malaysia, MYEG said it holds three-year rights to exclusively distribute the vaccine in Malaysia while through a separate partnership, the group has two-year exclusive distribution rights to the vaccine in the Philippines and is presently in discussions to distribute in other countries.
"Last week, MYEG announced plans for the roll-out of a vaccination programme in the Philippines that will cover the provision of the vaccines to the public health segment as well as private sales,” it said.
The LOI is to ensure that the corresponding quantity of Zhifei’s recombinant protein subunit vaccine is reserved for delivery as early as August when vaccination through the private market is enabled.
"This paves the way for the vaccine to be imported and made available to Malaysians as soon as the private market commences and subject to the conditional authorisation of the vaccine by the National Pharmaceutical Regulatory Agency (NPRA),” it said.
The cost of the vaccine will be determined later subject to the conditional authorisation by NPRA.
MYEG said it is confident that when the Zhifei vaccine becomes available locally, it can play an important role in accelerating the country’s drive towards achieving herd immunity against the COVID-19 virus.
Jointly developed by Zhifei and the Institute of Microbiology of the Chinese Academy of Sciences, the vaccine has fast emerged as among the preferred vaccines in China since gaining emergency use authorisation there in early March in view of its distinct inherent advantages as a recombinant protein subunit vaccine. More than 60 million doses have already been administered in more than a dozen provincial-level regions, including Beijing. The vaccine is also being used in Uzbekistan.
Recombinant protein technology is proven, having been used for the development of vaccines such as hepatitis B and shingles.
In addition, recombinant protein vaccines can be more easily produced at a large-scale since production does not need to be carried out in high-grade biosafety laboratories, and they are also more cost-effective and easier to store and transport.
Since the outbreak of the COVID-19 virus, MYEG has leveraged its strengths and expertise as a leading digital services provider in the region to introduce a number of significant initiatives as part of a holistic solution aimed at helping in the fight against the pandemic.
Besides vaccines, these offerings include screening services, quarantine management and digital health travel pass systems.
Stock
2021-06-26 00:58 | Report Abuse
KUALA LUMPUR (Bernama) -- My E.G. Services Bhd has signed a letter of intent (LOI) to purchase 10 million doses of Anhui Zhifei Biopharmaceutical Co Ltd’s COVID-19 vaccine, ensuring that the corresponding quantity of its recombinant protein subunit vaccine is reserved for delivery as early as August.
In a filing with Bursa Malaysia, MYEG said it holds three-year rights to exclusively distribute the vaccine in Malaysia while through a separate partnership, the group has two-year exclusive distribution rights to the vaccine in the Philippines and is presently in discussions to distribute in other countries.
"Last week, MYEG announced plans for the roll-out of a vaccination programme in the Philippines that will cover the provision of the vaccines to the public health segment as well as private sales,” it said.
The LOI is to ensure that the corresponding quantity of Zhifei’s recombinant protein subunit vaccine is reserved for delivery as early as August when vaccination through the private market is enabled.
"This paves the way for the vaccine to be imported and made available to Malaysians as soon as the private market commences and subject to the conditional authorisation of the vaccine by the National Pharmaceutical Regulatory Agency (NPRA),” it said.
The cost of the vaccine will be determined later subject to the conditional authorisation by NPRA.
MYEG said it is confident that when the Zhifei vaccine becomes available locally, it can play an important role in accelerating the country’s drive towards achieving herd immunity against the COVID-19 virus.
Jointly developed by Zhifei and the Institute of Microbiology of the Chinese Academy of Sciences, the vaccine has fast emerged as among the preferred vaccines in China since gaining emergency use authorisation there in early March in view of its distinct inherent advantages as a recombinant protein subunit vaccine. More than 60 million doses have already been administered in more than a dozen provincial-level regions, including Beijing. The vaccine is also being used in Uzbekistan.
Recombinant protein technology is proven, having been used for the development of vaccines such as hepatitis B and shingles.
In addition, recombinant protein vaccines can be more easily produced at a large-scale since production does not need to be carried out in high-grade biosafety laboratories, and they are also more cost-effective and easier to store and transport.
Since the outbreak of the COVID-19 virus, MYEG has leveraged its strengths and expertise as a leading digital services provider in the region to introduce a number of significant initiatives as part of a holistic solution aimed at helping in the fight against the pandemic.
Besides vaccines, these offerings include screening services, quarantine management and digital health travel pass systems.
Stock
2021-06-26 00:57 | Report Abuse
KUALA LUMPUR (Bernama) -- My E.G. Services Bhd has signed a letter of intent (LOI) to purchase 10 million doses of Anhui Zhifei Biopharmaceutical Co Ltd’s COVID-19 vaccine, ensuring that the corresponding quantity of its recombinant protein subunit vaccine is reserved for delivery as early as August.
In a filing with Bursa Malaysia, MYEG said it holds three-year rights to exclusively distribute the vaccine in Malaysia while through a separate partnership, the group has two-year exclusive distribution rights to the vaccine in the Philippines and is presently in discussions to distribute in other countries.
"Last week, MYEG announced plans for the roll-out of a vaccination programme in the Philippines that will cover the provision of the vaccines to the public health segment as well as private sales,” it said.
The LOI is to ensure that the corresponding quantity of Zhifei’s recombinant protein subunit vaccine is reserved for delivery as early as August when vaccination through the private market is enabled.
"This paves the way for the vaccine to be imported and made available to Malaysians as soon as the private market commences and subject to the conditional authorisation of the vaccine by the National Pharmaceutical Regulatory Agency (NPRA),” it said.
The cost of the vaccine will be determined later subject to the conditional authorisation by NPRA.
MYEG said it is confident that when the Zhifei vaccine becomes available locally, it can play an important role in accelerating the country’s drive towards achieving herd immunity against the COVID-19 virus.
Jointly developed by Zhifei and the Institute of Microbiology of the Chinese Academy of Sciences, the vaccine has fast emerged as among the preferred vaccines in China since gaining emergency use authorisation there in early March in view of its distinct inherent advantages as a recombinant protein subunit vaccine. More than 60 million doses have already been administered in more than a dozen provincial-level regions, including Beijing. The vaccine is also being used in Uzbekistan.
Recombinant protein technology is proven, having been used for the development of vaccines such as hepatitis B and shingles.
In addition, recombinant protein vaccines can be more easily produced at a large-scale since production does not need to be carried out in high-grade biosafety laboratories, and they are also more cost-effective and easier to store and transport.
Since the outbreak of the COVID-19 virus, MYEG has leveraged its strengths and expertise as a leading digital services provider in the region to introduce a number of significant initiatives as part of a holistic solution aimed at helping in the fight against the pandemic.
Besides vaccines, these offerings include screening services, quarantine management and digital health travel pass systems.
Stock
2021-06-26 00:57 | Report Abuse
KUALA LUMPUR (Bernama) -- My E.G. Services Bhd has signed a letter of intent (LOI) to purchase 10 million doses of Anhui Zhifei Biopharmaceutical Co Ltd’s COVID-19 vaccine, ensuring that the corresponding quantity of its recombinant protein subunit vaccine is reserved for delivery as early as August.
In a filing with Bursa Malaysia, MYEG said it holds three-year rights to exclusively distribute the vaccine in Malaysia while through a separate partnership, the group has two-year exclusive distribution rights to the vaccine in the Philippines and is presently in discussions to distribute in other countries.
"Last week, MYEG announced plans for the roll-out of a vaccination programme in the Philippines that will cover the provision of the vaccines to the public health segment as well as private sales,” it said.
The LOI is to ensure that the corresponding quantity of Zhifei’s recombinant protein subunit vaccine is reserved for delivery as early as August when vaccination through the private market is enabled.
"This paves the way for the vaccine to be imported and made available to Malaysians as soon as the private market commences and subject to the conditional authorisation of the vaccine by the National Pharmaceutical Regulatory Agency (NPRA),” it said.
The cost of the vaccine will be determined later subject to the conditional authorisation by NPRA.
MYEG said it is confident that when the Zhifei vaccine becomes available locally, it can play an important role in accelerating the country’s drive towards achieving herd immunity against the COVID-19 virus.
Jointly developed by Zhifei and the Institute of Microbiology of the Chinese Academy of Sciences, the vaccine has fast emerged as among the preferred vaccines in China since gaining emergency use authorisation there in early March in view of its distinct inherent advantages as a recombinant protein subunit vaccine. More than 60 million doses have already been administered in more than a dozen provincial-level regions, including Beijing. The vaccine is also being used in Uzbekistan.
Recombinant protein technology is proven, having been used for the development of vaccines such as hepatitis B and shingles.
In addition, recombinant protein vaccines can be more easily produced at a large-scale since production does not need to be carried out in high-grade biosafety laboratories, and they are also more cost-effective and easier to store and transport.
Since the outbreak of the COVID-19 virus, MYEG has leveraged its strengths and expertise as a leading digital services provider in the region to introduce a number of significant initiatives as part of a holistic solution aimed at helping in the fight against the pandemic.
Besides vaccines, these offerings include screening services, quarantine management and digital health travel pass systems.
Stock
2021-06-26 00:57 | Report Abuse
KUALA LUMPUR (Bernama) -- My E.G. Services Bhd has signed a letter of intent (LOI) to purchase 10 million doses of Anhui Zhifei Biopharmaceutical Co Ltd’s COVID-19 vaccine, ensuring that the corresponding quantity of its recombinant protein subunit vaccine is reserved for delivery as early as August.
In a filing with Bursa Malaysia, MYEG said it holds three-year rights to exclusively distribute the vaccine in Malaysia while through a separate partnership, the group has two-year exclusive distribution rights to the vaccine in the Philippines and is presently in discussions to distribute in other countries.
"Last week, MYEG announced plans for the roll-out of a vaccination programme in the Philippines that will cover the provision of the vaccines to the public health segment as well as private sales,” it said.
The LOI is to ensure that the corresponding quantity of Zhifei’s recombinant protein subunit vaccine is reserved for delivery as early as August when vaccination through the private market is enabled.
"This paves the way for the vaccine to be imported and made available to Malaysians as soon as the private market commences and subject to the conditional authorisation of the vaccine by the National Pharmaceutical Regulatory Agency (NPRA),” it said.
The cost of the vaccine will be determined later subject to the conditional authorisation by NPRA.
MYEG said it is confident that when the Zhifei vaccine becomes available locally, it can play an important role in accelerating the country’s drive towards achieving herd immunity against the COVID-19 virus.
Jointly developed by Zhifei and the Institute of Microbiology of the Chinese Academy of Sciences, the vaccine has fast emerged as among the preferred vaccines in China since gaining emergency use authorisation there in early March in view of its distinct inherent advantages as a recombinant protein subunit vaccine. More than 60 million doses have already been administered in more than a dozen provincial-level regions, including Beijing. The vaccine is also being used in Uzbekistan.
Recombinant protein technology is proven, having been used for the development of vaccines such as hepatitis B and shingles.
In addition, recombinant protein vaccines can be more easily produced at a large-scale since production does not need to be carried out in high-grade biosafety laboratories, and they are also more cost-effective and easier to store and transport.
Since the outbreak of the COVID-19 virus, MYEG has leveraged its strengths and expertise as a leading digital services provider in the region to introduce a number of significant initiatives as part of a holistic solution aimed at helping in the fight against the pandemic.
Besides vaccines, these offerings include screening services, quarantine management and digital health travel pass systems.
Stock
2021-06-26 00:56 | Report Abuse
KUALA LUMPUR (Bernama) -- My E.G. Services Bhd has signed a letter of intent (LOI) to purchase 10 million doses of Anhui Zhifei Biopharmaceutical Co Ltd’s COVID-19 vaccine, ensuring that the corresponding quantity of its recombinant protein subunit vaccine is reserved for delivery as early as August.
In a filing with Bursa Malaysia, MYEG said it holds three-year rights to exclusively distribute the vaccine in Malaysia while through a separate partnership, the group has two-year exclusive distribution rights to the vaccine in the Philippines and is presently in discussions to distribute in other countries.
"Last week, MYEG announced plans for the roll-out of a vaccination programme in the Philippines that will cover the provision of the vaccines to the public health segment as well as private sales,” it said.
The LOI is to ensure that the corresponding quantity of Zhifei’s recombinant protein subunit vaccine is reserved for delivery as early as August when vaccination through the private market is enabled.
"This paves the way for the vaccine to be imported and made available to Malaysians as soon as the private market commences and subject to the conditional authorisation of the vaccine by the National Pharmaceutical Regulatory Agency (NPRA),” it said.
The cost of the vaccine will be determined later subject to the conditional authorisation by NPRA.
MYEG said it is confident that when the Zhifei vaccine becomes available locally, it can play an important role in accelerating the country’s drive towards achieving herd immunity against the COVID-19 virus.
Jointly developed by Zhifei and the Institute of Microbiology of the Chinese Academy of Sciences, the vaccine has fast emerged as among the preferred vaccines in China since gaining emergency use authorisation there in early March in view of its distinct inherent advantages as a recombinant protein subunit vaccine. More than 60 million doses have already been administered in more than a dozen provincial-level regions, including Beijing. The vaccine is also being used in Uzbekistan.
Recombinant protein technology is proven, having been used for the development of vaccines such as hepatitis B and shingles.
In addition, recombinant protein vaccines can be more easily produced at a large-scale since production does not need to be carried out in high-grade biosafety laboratories, and they are also more cost-effective and easier to store and transport.
Since the outbreak of the COVID-19 virus, MYEG has leveraged its strengths and expertise as a leading digital services provider in the region to introduce a number of significant initiatives as part of a holistic solution aimed at helping in the fight against the pandemic.
Besides vaccines, these offerings include screening services, quarantine management and digital health travel pass systems.
Stock
2021-06-26 00:55 | Report Abuse
KUALA LUMPUR (Bernama) -- My E.G. Services Bhd has signed a letter of intent (LOI) to purchase 10 million doses of Anhui Zhifei Biopharmaceutical Co Ltd’s COVID-19 vaccine, ensuring that the corresponding quantity of its recombinant protein subunit vaccine is reserved for delivery as early as August.
In a filing with Bursa Malaysia, MYEG said it holds three-year rights to exclusively distribute the vaccine in Malaysia while through a separate partnership, the group has two-year exclusive distribution rights to the vaccine in the Philippines and is presently in discussions to distribute in other countries.
"Last week, MYEG announced plans for the roll-out of a vaccination programme in the Philippines that will cover the provision of the vaccines to the public health segment as well as private sales,” it said.
The LOI is to ensure that the corresponding quantity of Zhifei’s recombinant protein subunit vaccine is reserved for delivery as early as August when vaccination through the private market is enabled.
"This paves the way for the vaccine to be imported and made available to Malaysians as soon as the private market commences and subject to the conditional authorisation of the vaccine by the National Pharmaceutical Regulatory Agency (NPRA),” it said.
The cost of the vaccine will be determined later subject to the conditional authorisation by NPRA.
MYEG said it is confident that when the Zhifei vaccine becomes available locally, it can play an important role in accelerating the country’s drive towards achieving herd immunity against the COVID-19 virus.
Jointly developed by Zhifei and the Institute of Microbiology of the Chinese Academy of Sciences, the vaccine has fast emerged as among the preferred vaccines in China since gaining emergency use authorisation there in early March in view of its distinct inherent advantages as a recombinant protein subunit vaccine. More than 60 million doses have already been administered in more than a dozen provincial-level regions, including Beijing. The vaccine is also being used in Uzbekistan.
Recombinant protein technology is proven, having been used for the development of vaccines such as hepatitis B and shingles.
In addition, recombinant protein vaccines can be more easily produced at a large-scale since production does not need to be carried out in high-grade biosafety laboratories, and they are also more cost-effective and easier to store and transport.
Since the outbreak of the COVID-19 virus, MYEG has leveraged its strengths and expertise as a leading digital services provider in the region to introduce a number of significant initiatives as part of a holistic solution aimed at helping in the fight against the pandemic.
Besides vaccines, these offerings include screening services, quarantine management and digital health travel pass systems.
Stock
2021-06-26 00:55 | Report Abuse
KUALA LUMPUR (Bernama) -- My E.G. Services Bhd has signed a letter of intent (LOI) to purchase 10 million doses of Anhui Zhifei Biopharmaceutical Co Ltd’s COVID-19 vaccine, ensuring that the corresponding quantity of its recombinant protein subunit vaccine is reserved for delivery as early as August.
In a filing with Bursa Malaysia, MYEG said it holds three-year rights to exclusively distribute the vaccine in Malaysia while through a separate partnership, the group has two-year exclusive distribution rights to the vaccine in the Philippines and is presently in discussions to distribute in other countries.
"Last week, MYEG announced plans for the roll-out of a vaccination programme in the Philippines that will cover the provision of the vaccines to the public health segment as well as private sales,” it said.
The LOI is to ensure that the corresponding quantity of Zhifei’s recombinant protein subunit vaccine is reserved for delivery as early as August when vaccination through the private market is enabled.
"This paves the way for the vaccine to be imported and made available to Malaysians as soon as the private market commences and subject to the conditional authorisation of the vaccine by the National Pharmaceutical Regulatory Agency (NPRA),” it said.
The cost of the vaccine will be determined later subject to the conditional authorisation by NPRA.
MYEG said it is confident that when the Zhifei vaccine becomes available locally, it can play an important role in accelerating the country’s drive towards achieving herd immunity against the COVID-19 virus.
Jointly developed by Zhifei and the Institute of Microbiology of the Chinese Academy of Sciences, the vaccine has fast emerged as among the preferred vaccines in China since gaining emergency use authorisation there in early March in view of its distinct inherent advantages as a recombinant protein subunit vaccine. More than 60 million doses have already been administered in more than a dozen provincial-level regions, including Beijing. The vaccine is also being used in Uzbekistan.
Recombinant protein technology is proven, having been used for the development of vaccines such as hepatitis B and shingles.
In addition, recombinant protein vaccines can be more easily produced at a large-scale since production does not need to be carried out in high-grade biosafety laboratories, and they are also more cost-effective and easier to store and transport.
Since the outbreak of the COVID-19 virus, MYEG has leveraged its strengths and expertise as a leading digital services provider in the region to introduce a number of significant initiatives as part of a holistic solution aimed at helping in the fight against the pandemic.
Besides vaccines, these offerings include screening services, quarantine management and digital health travel pass systems.
Stock
2021-06-26 00:49 | Report Abuse
财经新闻
看好今年业务增长 龙合国际放眼67亿营收
2021年06月25日
（吉隆坡25日讯）尽管市况充满挑战，龙合国际（LHI，6633，主板消费股）对于旗下业务增长前景保持信心，今年营收目标介于65亿至67亿令吉。
执行董事兼集团总执行长丹斯里刘团源，今日在股东大会后的线上记者会上指出，有信心今年营收可增长10%。
集团财务总监周永乐也指出，集团在2021财年首季业绩取得不错的表现，随着疫苗接种计划进行，对于今年前景保持乐观态度，并预计明年会更好。
龙合国际在2020财年，取得60亿4066万4000令吉营收，净利则录得1亿1314万6000令吉。
该集团今天在文告中指出，会致力于加强“农场到餐桌”（Farm-to-Plate）的业务概念，进一步整合下游业务链，和综合市场带来的内生增长。
刘团源在今日线上记者会分享龙合国际前景。
印尼新厂年底完工
为此，该集团正在印尼西爪哇省建设一家新家禽加工厂，预计今年底完工。
另外，随着吕宋岛中部萨邦首家饲料厂即将投产，菲律宾饲料业务的产能可提高至每年最多12万8000吨。
龙合国际的业务遍布东南亚。在2020财年，印尼业务贡献该集团33%营收，其次是大马和越南，分别贡献27%和26%。新加坡和菲律宾则分别贡献12%和2%。
刘团源也透露，集团接下来有意开拓柬埔寨和缅甸市场。
2年内增144麦可思分店
执行董事兼大马总执行长刘裕汉指出，将在2年内扩张麦可思分店数量至280间，并放眼该业务在2023年可贡献集团约4亿令吉营业额。
他透露，目前麦可思拥有136间分行，贡献该集团约3%营收，预计在扩张至280间后，可贡献集团约6%营收。
Stock
2021-06-26 00:49 | Report Abuse
财经新闻
看好今年业务增长 龙合国际放眼67亿营收
2021年06月25日
（吉隆坡25日讯）尽管市况充满挑战，龙合国际（LHI，6633，主板消费股）对于旗下业务增长前景保持信心，今年营收目标介于65亿至67亿令吉。
执行董事兼集团总执行长丹斯里刘团源，今日在股东大会后的线上记者会上指出，有信心今年营收可增长10%。
集团财务总监周永乐也指出，集团在2021财年首季业绩取得不错的表现，随着疫苗接种计划进行，对于今年前景保持乐观态度，并预计明年会更好。
龙合国际在2020财年，取得60亿4066万4000令吉营收，净利则录得1亿1314万6000令吉。
该集团今天在文告中指出，会致力于加强“农场到餐桌”（Farm-to-Plate）的业务概念，进一步整合下游业务链，和综合市场带来的内生增长。
刘团源在今日线上记者会分享龙合国际前景。
印尼新厂年底完工
为此，该集团正在印尼西爪哇省建设一家新家禽加工厂，预计今年底完工。
另外，随着吕宋岛中部萨邦首家饲料厂即将投产，菲律宾饲料业务的产能可提高至每年最多12万8000吨。
龙合国际的业务遍布东南亚。在2020财年，印尼业务贡献该集团33%营收，其次是大马和越南，分别贡献27%和26%。新加坡和菲律宾则分别贡献12%和2%。
刘团源也透露，集团接下来有意开拓柬埔寨和缅甸市场。
2年内增144麦可思分店
执行董事兼大马总执行长刘裕汉指出，将在2年内扩张麦可思分店数量至280间，并放眼该业务在2023年可贡献集团约4亿令吉营业额。
他透露，目前麦可思拥有136间分行，贡献该集团约3%营收，预计在扩张至280间后，可贡献集团约6%营收。
Stock
2021-06-26 00:48 | Report Abuse
财经新闻
看好今年业务增长 龙合国际放眼67亿营收
2021年06月25日
（吉隆坡25日讯）尽管市况充满挑战，龙合国际（LHI，6633，主板消费股）对于旗下业务增长前景保持信心，今年营收目标介于65亿至67亿令吉。
执行董事兼集团总执行长丹斯里刘团源，今日在股东大会后的线上记者会上指出，有信心今年营收可增长10%。
集团财务总监周永乐也指出，集团在2021财年首季业绩取得不错的表现，随着疫苗接种计划进行，对于今年前景保持乐观态度，并预计明年会更好。
龙合国际在2020财年，取得60亿4066万4000令吉营收，净利则录得1亿1314万6000令吉。
该集团今天在文告中指出，会致力于加强“农场到餐桌”（Farm-to-Plate）的业务概念，进一步整合下游业务链，和综合市场带来的内生增长。
刘团源在今日线上记者会分享龙合国际前景。
印尼新厂年底完工
为此，该集团正在印尼西爪哇省建设一家新家禽加工厂，预计今年底完工。
另外，随着吕宋岛中部萨邦首家饲料厂即将投产，菲律宾饲料业务的产能可提高至每年最多12万8000吨。
龙合国际的业务遍布东南亚。在2020财年，印尼业务贡献该集团33%营收，其次是大马和越南，分别贡献27%和26%。新加坡和菲律宾则分别贡献12%和2%。
刘团源也透露，集团接下来有意开拓柬埔寨和缅甸市场。
2年内增144麦可思分店
执行董事兼大马总执行长刘裕汉指出，将在2年内扩张麦可思分店数量至280间，并放眼该业务在2023年可贡献集团约4亿令吉营业额。
他透露，目前麦可思拥有136间分行，贡献该集团约3%营收，预计在扩张至280间后，可贡献集团约6%营收。
Stock
2021-06-26 00:47 | Report Abuse
刘团源在今日线上记者会分享龙合国际前景。
印尼新厂年底完工
为此，该集团正在印尼西爪哇省建设一家新家禽加工厂，预计今年底完工。
另外，随着吕宋岛中部萨邦首家饲料厂即将投产，菲律宾饲料业务的产能可提高至每年最多12万8000吨。
龙合国际的业务遍布东南亚。在2020财年，印尼业务贡献该集团33%营收，其次是大马和越南，分别贡献27%和26%。新加坡和菲律宾则分别贡献12%和2%。
刘团源也透露，集团接下来有意开拓柬埔寨和缅甸市场。
2年内增144麦可思分店
执行董事兼大马总执行长刘裕汉指出，将在2年内扩张麦可思分店数量至280间，并放眼该业务在2023年可贡献集团约4亿令吉营业额。
他透露，目前麦可思拥有136间分行，贡献该集团约3%营收，预计在扩张至280间后，可贡献集团约6%营收。
Stock
2021-06-26 00:46 | Report Abuse
集团财务总监周永乐也指出，集团在2021财年首季业绩取得不错的表现，随着疫苗接种计划进行，对于今年前景保持乐观态度，并预计明年会更好。
龙合国际在2020财年，取得60亿4066万4000令吉营收，净利则录得1亿1314万6000令吉。
该集团今天在文告中指出，会致力于加强“农场到餐桌”（Farm-to-Plate）的业务概念，进一步整合下游业务链，和综合市场带来的内生增长。
Stock
2021-06-26 00:45 | Report Abuse
财经新闻
看好今年业务增长 龙合国际放眼67亿营收
2021年06月25日
（吉隆坡25日讯）尽管市况充满挑战，龙合国际（LHI，6633，主板消费股）对于旗下业务增长前景保持信心，今年营收目标介于65亿至67亿令吉。
执行董事兼集团总执行长丹斯里刘团源，今日在股东大会后的线上记者会上指出，有信心今年营收可增长10%。
Stock
2021-06-26 00:43 | Report Abuse
财经新闻
MYEG计划8月起供应1000万剂疫苗
2021年06月25日
（吉隆坡25日讯）MYEG（MYEG，0138，主板科技股）计划今年8月起，在国内供应1000万剂疫苗。
MYEG周五发文告指出，已和安徽智飞生物制药公司签署意向书，向后者购买1000万剂疫苗，并在8月起供应予国人。
相关成本待定。同时，正式分发疫苗前，需获得国家药剂监管机构（NPRA）的批准。
“公司有信心，疫苗获准在国内分发后，将加速推动我国走向全民免疫。”
周五闭市，MYEG收报1.82令吉，无起落，交易量约为843万股。
Stock
2021-06-26 00:43 | Report Abuse
财经新闻
MYEG计划8月起供应1000万剂疫苗
2021年06月25日
（吉隆坡25日讯）MYEG（MYEG，0138，主板科技股）计划今年8月起，在国内供应1000万剂疫苗。
MYEG周五发文告指出，已和安徽智飞生物制药公司签署意向书，向后者购买1000万剂疫苗，并在8月起供应予国人。
相关成本待定。同时，正式分发疫苗前，需获得国家药剂监管机构（NPRA）的批准。
“公司有信心，疫苗获准在国内分发后，将加速推动我国走向全民免疫。”
周五闭市，MYEG收报1.82令吉，无起落，交易量约为843万股。
Stock
2021-06-26 00:43 | Report Abuse
财经新闻
MYEG计划8月起供应1000万剂疫苗
2021年06月25日
（吉隆坡25日讯）MYEG（MYEG，0138，主板科技股）计划今年8月起，在国内供应1000万剂疫苗。
MYEG周五发文告指出，已和安徽智飞生物制药公司签署意向书，向后者购买1000万剂疫苗，并在8月起供应予国人。
相关成本待定。同时，正式分发疫苗前，需获得国家药剂监管机构（NPRA）的批准。
“公司有信心，疫苗获准在国内分发后，将加速推动我国走向全民免疫。”
周五闭市，MYEG收报1.82令吉，无起落，交易量约为843万股。
Stock
2021-06-26 00:42 | Report Abuse
财经新闻
MYEG计划8月起供应1000万剂疫苗
2021年06月25日
（吉隆坡25日讯）MYEG（MYEG，0138，主板科技股）计划今年8月起，在国内供应1000万剂疫苗。
MYEG周五发文告指出，已和安徽智飞生物制药公司签署意向书，向后者购买1000万剂疫苗，并在8月起供应予国人。
相关成本待定。同时，正式分发疫苗前，需获得国家药剂监管机构（NPRA）的批准。
“公司有信心，疫苗获准在国内分发后，将加速推动我国走向全民免疫。”
周五闭市，MYEG收报1.82令吉，无起落，交易量约为843万股。
Stock
2021-06-26 00:42 | Report Abuse
财经新闻
MYEG计划8月起供应1000万剂疫苗
2021年06月25日
（吉隆坡25日讯）MYEG（MYEG，0138，主板科技股）计划今年8月起，在国内供应1000万剂疫苗。
MYEG周五发文告指出，已和安徽智飞生物制药公司签署意向书，向后者购买1000万剂疫苗，并在8月起供应予国人。
相关成本待定。同时，正式分发疫苗前，需获得国家药剂监管机构（NPRA）的批准。
“公司有信心，疫苗获准在国内分发后，将加速推动我国走向全民免疫。”
周五闭市，MYEG收报1.82令吉，无起落，交易量约为843万股。
Stock
2021-06-26 00:41 | Report Abuse
财经新闻
MYEG计划8月起供应1000万剂疫苗
2021年06月25日
（吉隆坡25日讯）MYEG（MYEG，0138，主板科技股）计划今年8月起，在国内供应1000万剂疫苗。
MYEG周五发文告指出，已和安徽智飞生物制药公司签署意向书，向后者购买1000万剂疫苗，并在8月起供应予国人。
相关成本待定。同时，正式分发疫苗前，需获得国家药剂监管机构（NPRA）的批准。
“公司有信心，疫苗获准在国内分发后，将加速推动我国走向全民免疫。”
周五闭市，MYEG收报1.82令吉，无起落，交易量约为843万股。
Stock
2021-06-26 00:39 | Report Abuse
相关成本待定。同时，正式分发疫苗前，需获得国家药剂监管机构（NPRA）的批准。
“公司有信心，疫苗获准在国内分发后，将加速推动我国走向全民免疫。”
周五闭市，MYEG收报1.82令吉，无起落，交易量约为843万股。
Stock
2021-06-26 00:38 | Report Abuse
财经新闻
MYEG计划8月起供应1000万剂疫苗
2021年06月25日
（吉隆坡25日讯）MYEG（MYEG，0138，主板科技股）计划今年8月起，在国内供应1000万剂疫苗。
MYEG周五发文告指出，已和安徽智飞生物制药公司签署意向书，向后者购买1000万剂疫苗，并在8月起供应予国人。
Stock
2021-06-23 23:40 | Report Abuse
This is GENERAL MEETINGS: Outcome of Meeting not AGM minutes. Should have a AGM minutes & waiting!
Stock
2021-06-23 21:48 | Report Abuse
All tipu makan one & thought themselves are the GOD..
Stock
2021-06-23 21:47 | Report Abuse
Don’t simply trust FB live teachers too
Stock
2021-06-23 19:46 | Report Abuse
Alo @Trust . Hope you are interested in QES，
Kindly help to remove this faked YouTube.
Don’t care about this ah tu and ah kau.
Both of them really tak Ada knowledge of tech counter at all
Stock
2021-06-23 19:42 | Report Abuse
LOOKING up at its bigger peers, Shah Alam-based automated test equipment (ATE) manufacturer QES Group Bhd can already see itself among their ranks in the not-too-distant future.
Also its largest shareholder, QES managing director and president Chew Ne Weng, is not shy about the group’s ambition to become an equipment giant.
“People often ask me whether QES can be as big as ViTrox, Pentamaster, Greatech and MI Technovation. I don’t discount such possibilities. That’s our plan actually. It is where we want to be one day. To me, it is all about hitting the volume and scale,” he tells The Edge in a virtual interview.
According to him, the fixed costs of QES’ manufacturing business is expected to reach a constant level, and when it reaches an inflection point, any additional revenue that comes in will largely be profit.
“I would say we are at the 60% to 70% level of reaching that inflection point. We will scale it up, and once we hit the inflection point, our profit will grow significantly within the next two to three years. By then, hopefully, our market capitalisation could reach RM1 billion,” says Chew.
Year to date, shares in QES have more than doubled. The stock closed at 62 sen last Thursday, which translates into a market capitalisation of RM517.17 million. In comparison, its better known peers MI Technovation, Pentamaster, Greatech and ViTrox have a market capitalisation of between RM2.56 billion and RM7.34 billion.
QES started in 1991 as a distributor of test, inspection and measuring equipment, before eventually becoming a manufacturer of these equipment. Today, the group has two core business divisions — namely, distribution and manufacturing.
Following the company’s listing on the ACE Market of Bursa Malaysia in 2018, many investors and fund managers have expressed particular interest in its manufacturing division, which makes equipment for the semiconductor industry.
“We have quite a large spectrum of product lines, covering various test and inspection processes, from wafer fabs all the way to test and assembly. We have all the equipment for wafer inspection, post-wafer probing and post-dicing, wafer sorting and handling, as well as wafer packing and unpacking,” Chew elaborates.
“The only area that we don’t cover is the final test, which we think is a very crowded space. The likes of ViTrox and Pentamaster are covering this area, while many other non-listed local players are there too,” he explains.
In the distribution business, QES distributes the products of principals — from countries such as Japan, the US and Europe — in the Asean region.
“We have offices in Malaysia, Singapore, Thailand, Indonesia, the Philippines and Vietnam. Of course, we also sell our own products in these markets, but the product range is different as we don’t want to compete directly with our principals,” stresses 58-year-old Chew, who co-founded QES and is the single largest shareholder with a 30.84% stake in the company.
Despite posting a slight dip in revenue in the financial year ended Dec 31, 2020, QES’ earnings jumped 2.6 times to RM8.7 million from RM3.3 million a year ago.
In the first quarter ended March 31, 2021, net profit soared to a new record high of RM6.9 million, representing a year-on-year growth of 176% from RM2.49 million a year earlier. As at March 31, cash and cash equivalents stood at RM69.4 million.
Commenting on stock valuations, Chew observes that QES had been trading at a historical price-earnings ratio (PER) of more than 60 times. But in the aftermath of its latest financial results on May 19, its PER has been reduced substantially to about 38 times currently.
“If you compare our PER with other ATE manufacturers, you will realise that QES has a good value proposition. Our stock valuation still appears to be rather attractive,” he asserts.
Expanding manufacturing business
Currently, 16% to 18% of QES’ revenue comes from its manufacturing division, and the remaining 80%-plus from its distribution division.
The beauty of QES’ distribution business, Chew points out, is that it provides the group with a huge chunk of recurring income, given that it had installed more than 12,000 units of equipment in the Asean region and other parts of the world over the past 30 years.
“These equipment need to be maintained and serviced regularly. Every year, we would consistently collect a recurring income of about RM40 million, which constitutes 20% to 25% of our group revenue. In other words, our recurring income from the distribution division alone is bigger than our manufacturing division.”
Nevertheless, the manufacturing division will remain a key pillar to be built up over the next two to three years. “We hope the manufacturing business [will be able to] contribute up to 30%-40% of our group revenue. This is one area that we think we can grow exponentially,” says Chew.
Unlike its distribution business — where it is an Asean specialist but still needs to follow its principals’ strategic dire
Stock
2021-06-23 19:40 | Report Abuse
Sorry I know both of them. Siapa dia pig head ? Haha.
People without knowledge of share market.
I don’t want waste my time to listen the above YouTube. Sendiri wayang sendiri song. Shit
Stock
Stock
2021-06-23 10:00 | Report Abuse
The Board of Directors of Willowglen MSC Berhad (“the Company”) is pleased to announce that on 21 June 2021, the Company’s wholly-owned subsidiary, Willowglen Services Pte. Ltd. has been awarded a contract valued equivalent to approximately RM10,990,000 by SP PowerAssets Limited, Singapore for the Comprehensive Maintenance of East-West Cable Tunnel (EWCT) Scada System, including system enhancements.
The commencement date of the contract is on 22 June 2021 and will be completed by 21 June 2026.
The contract is expected to contribute positively to the Group’s earnings and net assets per share for the financial years ending 31 December 2021 to 2026.
The contract is not renewable and the risks in respect of the contract are the normal business risks.
None of the directors and / or major shareholders of the Company or persons connected to them has any interest, direct or indirect in the new contract awarded.
This announcement is dated 22 June 2021.
Stock
2021-06-17 20:24 | Report Abuse
TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) : NON RELATED PARTY TRANSACTIONS MY E.G. Services Berhad ("MYEG" or "the Company") - Joint Venture Agreements entered between:- (1) Shigatse Service Co., Ltd. and MYEG Medical Services Sdn. Bhd., a wholly-owned sub-subsidiary of the Company; and (2) SinoPhil Biotech Inc., Shigatse Service Co., Ltd. and I-PAY MYEG Philippines Inc., a joint venture company of the Company.
MY E.G. SERVICES BERHAD
Type Announcement
Subject TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS)
NON RELATED PARTY TRANSACTIONS
Description MY E.G. Services Berhad ("MYEG" or "the Company")
- Joint Venture Agreements entered between:-
(1) Shigatse Service Co., Ltd. and MYEG Medical Services Sdn. Bhd., a wholly-owned sub-subsidiary of the Company; and
(2) SinoPhil Biotech Inc., Shigatse Service Co., Ltd. and I-PAY MYEG Philippines Inc., a joint venture company of the Company.
The Board of Directors of the Company wishes to announce that MYEG Medical Services Sdn. Bhd., a wholly-owned sub-subsidiary of the Company and I-Pay MYEG Philippines Inc., a joint venture company of the Company, had on 17 June 2021 entered into joint venture agreements respectively in their respective territories.
Please refer to the attachment for further details.
This announcement is dated 17 June 2021.
Stock
2021-06-17 20:23 | Report Abuse
TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) : NON RELATED PARTY TRANSACTIONS MY E.G. Services Berhad ("MYEG" or "the Company") - Joint Venture Agreements entered between:- (1) Shigatse Service Co., Ltd. and MYEG Medical Services Sdn. Bhd., a wholly-owned sub-subsidiary of the Company; and (2) SinoPhil Biotech Inc., Shigatse Service Co., Ltd. and I-PAY MYEG Philippines Inc., a joint venture company of the Company.
MY E.G. SERVICES BERHAD
Type Announcement
Subject TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS)
NON RELATED PARTY TRANSACTIONS
Description MY E.G. Services Berhad ("MYEG" or "the Company")
- Joint Venture Agreements entered between:-
(1) Shigatse Service Co., Ltd. and MYEG Medical Services Sdn. Bhd., a wholly-owned sub-subsidiary of the Company; and
(2) SinoPhil Biotech Inc., Shigatse Service Co., Ltd. and I-PAY MYEG Philippines Inc., a joint venture company of the Company.
The Board of Directors of the Company wishes to announce that MYEG Medical Services Sdn. Bhd., a wholly-owned sub-subsidiary of the Company and I-Pay MYEG Philippines Inc., a joint venture company of the Company, had on 17 June 2021 entered into joint venture agreements respectively in their respective territories.
Please refer to the attachment for further details.
This announcement is dated 17 June 2021.
Stock
2021-06-17 20:23 | Report Abuse
TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) : NON RELATED PARTY TRANSACTIONS MY E.G. Services Berhad ("MYEG" or "the Company") - Joint Venture Agreements entered between:- (1) Shigatse Service Co., Ltd. and MYEG Medical Services Sdn. Bhd., a wholly-owned sub-subsidiary of the Company; and (2) SinoPhil Biotech Inc., Shigatse Service Co., Ltd. and I-PAY MYEG Philippines Inc., a joint venture company of the Company.
MY E.G. SERVICES BERHAD
Type Announcement
Subject TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS)
NON RELATED PARTY TRANSACTIONS
Description MY E.G. Services Berhad ("MYEG" or "the Company")
- Joint Venture Agreements entered between:-
(1) Shigatse Service Co., Ltd. and MYEG Medical Services Sdn. Bhd., a wholly-owned sub-subsidiary of the Company; and
(2) SinoPhil Biotech Inc., Shigatse Service Co., Ltd. and I-PAY MYEG Philippines Inc., a joint venture company of the Company.
The Board of Directors of the Company wishes to announce that MYEG Medical Services Sdn. Bhd., a wholly-owned sub-subsidiary of the Company and I-Pay MYEG Philippines Inc., a joint venture company of the Company, had on 17 June 2021 entered into joint venture agreements respectively in their respective territories.
Please refer to the attachment for further details.
This announcement is dated 17 June 2021.
Stock
2021-06-17 20:22 | Report Abuse
TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) : NON RELATED PARTY TRANSACTIONS MY E.G. Services Berhad ("MYEG" or "the Company") - Joint Venture Agreements entered between:- (1) Shigatse Service Co., Ltd. and MYEG Medical Services Sdn. Bhd., a wholly-owned sub-subsidiary of the Company; and (2) SinoPhil Biotech Inc., Shigatse Service Co., Ltd. and I-PAY MYEG Philippines Inc., a joint venture company of the Company.
MY E.G. SERVICES BERHAD
Type Announcement
Subject TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS)
NON RELATED PARTY TRANSACTIONS
Description MY E.G. Services Berhad ("MYEG" or "the Company")
- Joint Venture Agreements entered between:-
(1) Shigatse Service Co., Ltd. and MYEG Medical Services Sdn. Bhd., a wholly-owned sub-subsidiary of the Company; and
(2) SinoPhil Biotech Inc., Shigatse Service Co., Ltd. and I-PAY MYEG Philippines Inc., a joint venture company of the Company.
The Board of Directors of the Company wishes to announce that MYEG Medical Services Sdn. Bhd., a wholly-owned sub-subsidiary of the Company and I-Pay MYEG Philippines Inc., a joint venture company of the Company, had on 17 June 2021 entered into joint venture agreements respectively in their respective territories.
Please refer to the attachment for further details.
This announcement is dated 17 June 2021.
Stock
2021-06-17 20:22 | Report Abuse
OTHERS MY E.G. Services Berhad (''MYEG'' or the ''Company'') - Press Release: MYEG partners SinoPhil Biotech and Health Direct Now for COVID-19 vaccination programme in the Philippines
MY E.G. SERVICES BERHAD
Type Announcement
Subject OTHERS
Description MY E.G. Services Berhad (''MYEG'' or the ''Company'')
- Press Release: MYEG partners SinoPhil Biotech and Health Direct Now for COVID-19 vaccination programme in the Philippines
The Board of Directors of the Company wishes to announce that the Company has through its joint venture company, I-Pay MYEG Philippines, Inc., entered into a strategic partnership with SinoPhil Biotech, Inc. and Family Vaccine and Specialty Clinics, Inc.’s Health Direct Now initiative for the provision of a COVID-19 vaccination programme in the Philippines (“the Partnership”).
The Board of Directors is of the view that, barring any unforeseen circumstances, the Partnership is expected to contribute positively to the earnings per share and net assets per share of the Group for the financial year ending 31 December 2021 and onwards. The prospects of the Partnership is also expected to be positive.
Please refer to the attachment in relation to the press release for further details.
This announcement is dated 17 June 2021.
Stock
2021-06-17 20:21 | Report Abuse
OTHERS MY E.G. Services Berhad (''MYEG'' or the ''Company'') - Press Release: MYEG partners SinoPhil Biotech and Health Direct Now for COVID-19 vaccination programme in the Philippines
MY E.G. SERVICES BERHAD
Type Announcement
Subject OTHERS
Description MY E.G. Services Berhad (''MYEG'' or the ''Company'')
- Press Release: MYEG partners SinoPhil Biotech and Health Direct Now for COVID-19 vaccination programme in the Philippines
The Board of Directors of the Company wishes to announce that the Company has through its joint venture company, I-Pay MYEG Philippines, Inc., entered into a strategic partnership with SinoPhil Biotech, Inc. and Family Vaccine and Specialty Clinics, Inc.’s Health Direct Now initiative for the provision of a COVID-19 vaccination programme in the Philippines (“the Partnership”).
The Board of Directors is of the view that, barring any unforeseen circumstances, the Partnership is expected to contribute positively to the earnings per share and net assets per share of the Group for the financial year ending 31 December 2021 and onwards. The prospects of the Partnership is also expected to be positive.
Please refer to the attachment in relation to the press release for further details.
This announcement is dated 17 June 2021.
Stock
2021-06-17 20:21 | Report Abuse
OTHERS MY E.G. Services Berhad (''MYEG'' or the ''Company'') - Press Release: MYEG partners SinoPhil Biotech and Health Direct Now for COVID-19 vaccination programme in the Philippines
MY E.G. SERVICES BERHAD
Type Announcement
Subject OTHERS
Description MY E.G. Services Berhad (''MYEG'' or the ''Company'')
- Press Release: MYEG partners SinoPhil Biotech and Health Direct Now for COVID-19 vaccination programme in the Philippines
The Board of Directors of the Company wishes to announce that the Company has through its joint venture company, I-Pay MYEG Philippines, Inc., entered into a strategic partnership with SinoPhil Biotech, Inc. and Family Vaccine and Specialty Clinics, Inc.’s Health Direct Now initiative for the provision of a COVID-19 vaccination programme in the Philippines (“the Partnership”).
The Board of Directors is of the view that, barring any unforeseen circumstances, the Partnership is expected to contribute positively to the earnings per share and net assets per share of the Group for the financial year ending 31 December 2021 and onwards. The prospects of the Partnership is also expected to be positive.
Please refer to the attachment in relation to the press release for further details.
This announcement is dated 17 June 2021.
Stock
Stock
Stock
Stock
Stock
Stock
Stock
2021-06-10 09:48 | Report Abuse
Directors ONLY disposed 14 millions shares.
Both hold over 440 millions of share.
Stock
Stock
2021-06-09 15:47 | Report Abuse
Alo Didn’t surprised.. disposed only 14 millions shares. Both hold over 400 millions of share.
Stock
Stock
2021-06-09 15:22 | Report Abuse
Edge Weekly - Chew: People often ask me whether QES can be as big as ViTrox, Pentamaster, Greatech and MI Technovation. I don’t discount such possibilities. That’s our plan actually. (Photo by Patrick Goh/The Edge) - http://www.theedgemarkets.com/article/qes-group-aims-be-bigname-equipment-player (Share from StockHunter)
Stock
2021-06-09 15:20 | Report Abuse
Chew : People often ask me whether QES can be as big as ViTrox, Pentamaster, Greatech and MI Technovation. I don’t discount such possibilities. That’s our plan actually. (Photo by Patrick Goh/The Edge)
-A+A
LOOKING up at its bigger peers, Shah Alam-based automated test equipment (ATE) manufacturer QES Group Bhd can already see itself among their ranks in the not-too-distant future.
Also its largest shareholder, QES managing director and president Chew Ne Weng, is not shy about the group’s ambition to become an equipment giant.
“People often ask me whether QES can be as big as ViTrox, Pentamaster, Greatech and MI Technovation. I don’t discount such possibilities. That’s our plan actually. It is where we want to be one day. To me, it is all about hitting the volume and scale,” he tells The Edge in a virtual interview.
Advertisement
According to him, the fixed costs of QES’ manufacturing business is expected to reach a constant level, and when it reaches an inflection point, any additional revenue that comes in will largely be profit.
“I would say we are at the 60% to 70% level of reaching that inflection point. We will scale it up, and once we hit the inflection point, our profit will grow significantly within the next two to three years. By then, hopefully, our market capitalisation could reach RM1 billion,” says Chew.
Year to date, shares in QES have more than doubled. The stock closed at 62 sen last Thursday, which translates into a market capitalisation of RM517.17 million. In comparison, its better known peers MI Technovation, Pentamaster, Greatech and ViTrox have a market capitalisation of between RM2.56 billion and RM7.34 billion.
QES started in 1991 as a distributor of test, inspection and measuring equipment, before eventually becoming a manufacturer of these equipment. Today, the group has two core business divisions — namely, distribution and manufacturing.
Following the company’s listing on the ACE Market of Bursa Malaysia in 2018, many investors and fund managers have expressed particular interest in its manufacturing division, which makes equipment for the semiconductor industry.
“We have quite a large spectrum of product lines, covering various test and inspection processes, from wafer fabs all the way to test and assembly. We have all the equipment for wafer inspection, post-wafer probing and post-dicing, wafer sorting and handling, as well as wafer packing and unpacking,” Chew elaborates.
“The only area that we don’t cover is the final test, which we think is a very crowded space. The likes of ViTrox and Pentamaster are covering this area, while many other non-listed local players are there too,” he explains.
In the distribution business, QES distributes the products of principals — from countries such as Japan, the US and Europe — in the Asean region.
“We have offices in Malaysia, Singapore, Thailand, Indonesia, the Philippines and Vietnam. Of course, we also sell our own products in these markets, but the product range is different as we don’t want to compete directly with our principals,” stresses 58-year-old Chew, who co-founded QES and is the single largest shareholder with a 30.84% stake in the company.
Despite posting a slight dip in revenue in the financial year ended Dec 31, 2020, QES’ earnings jumped 2.6 times to RM8.7 million from RM3.3 million a year ago.
In the first quarter ended March 31, 2021, net profit soared to a new record high of RM6.9 million, representing a year-on-year growth of 176% from RM2.49 million a year earlier. As at March 31, cash and cash equivalents stood at RM69.4 million.
Commenting on stock valuations, Chew observes that QES had been trading at a historical price-earnings ratio (PER) of more than 60 times. But in the aftermath of its latest financial results on May 19, its PER has been reduced substantially to about 38 times currently.
“If you compare our PER with other ATE manufacturers, you will realise that QES has a good value proposition. Our stock valuation still appears to be rather attractive,” he asserts.
Expanding manufacturing business
Currently, 16% to 18% of QES’ revenue comes from its manufacturing division, and the remaining 80%-plus from its distribution division.
The beauty of QES’ distribution business, Chew points out, is that it provides the group with a huge chunk of recurring income, given that it had installed more than 12,000 units of equipment in the Asean region and other parts of the world over the past 30 years.
“These equipment need to be maintained and serviced regularly. Every year, we would consistently collect a recurring income of about RM40 million, which constitutes 20% to 25% of our group revenue. In other words, our recurring income from the distribution division alone is bigger than our manufacturing division.”
Nevertheless, the manufacturing division will remain a key pillar to be built up over the next two to three years. “We hope the manufacturing business [will be able to] contribute up to 30
Stock: [PMBTECH]: PMB TECHNOLOGY BHD
2021-06-29 23:24 | Report Abuse
******U.S. bans imports of solar panel material from Chinese company
Michael MartinaKaren FreifeldDavid Shepardson
June 23 (Reuters) - The Biden administration on Wednesday ordered a ban on U.S. imports of a key solar panel material from Chinese-based Hoshine Silicon Industry Co (603260.SS) over forced labor allegations, two sources briefed on the matter said.
The U.S. Commerce Department separately restricted exports to Hoshine, three other Chinese companies and the paramilitary Xinjiang Production and Construction Corps (XPCC), saying they were involved with the forced labor of Uyghurs and other Muslim minority groups in Xinjiang.
Reacting on Thursday, China's foreign ministry spokesman Zhao Lijian said China will take "all necessary measures" to protect its companies' rights and interests. Beijing has dismissed accusations of genocide and forced labor in Xinjiang as lies.
The three other companies added to the U.S. economic blacklist include Xinjiang Daqo New Energy Co, a unit of Daqo New Energy Corp (DQ.N); Xinjiang East Hope Nonferrous Metals Co, a subsidiary of Shanghai-based manufacturing giant East Hope Group; and Xinjiang GCL New Energy Material Co, part of GCL New Energy Holdings Ltd (0451.HK).
The Commerce Department said the companies and a paramilitary force, XPCC, "have been implicated in human rights violations and abuses in the implementation of China’s campaign of repression, mass arbitrary detention, forced labor and high-technology surveillance against Uyghurs, Kazakhs, and other members of Muslim minority groups in" Xinjiang.
At least some of the companies listed by the Commerce Department are major manufacturers of monocrystalline silicon and polysilicon that are used in solar panel production.
Hoshine Silicon Industry said on an interactive investor platform that it backed the Chinese foreign ministry's reaction, adding that the firm does not export industrial silicon to the United States directly and the impact on its business would be limited.
Xinjiang Daqo New Energy Co responded Reuters' request for comment with an email saying the company has "zero tolerance" towards forced labour, and that it does not sell directly to U.S. companies, or purchase from the United States and there would not be "a significant impact on the company’s business."
The other companies or their parent firms did not immediately respond to requests for comment, or could not immediately be reached. XPCC could not immediately be reached for comment.
The "Withhold Release Order" by U.S. Customs and Border Protection only blocks imports of the material from Hoshine. A source familiar with the order said it does not impact the majority of U.S. imports of polysilicon and other silica-based products.
U.S. and Chinese flags are seen in front of a U.S. dollar banknote featuring American founding father Benjamin Franklin and a China's yuan banknote featuring late Chinese chairman Mao Zedong in this illustration picture taken May 20, 2019. REUTERS/Jason Lee/Illustration/File Photo
Chinese and U.S. flags flutter outside a company building in Shanghai, China April 14, 2021. REUTERS/Aly Song/File Photo
Employees inspect newly-made solar panels on the roof of a Sungrow Power Supply Co., Ltd factory in Hefei, Anhui province December 8, 2010. REUTERS/Stringer
Dennis Ip, Regional Head of Power, Utilities, Renewables & Environment (PURE) Research at Daiwa said in a note to clients the immediate effect of the restrictions would be limited as the companies named do not have "vast contracts" with U.S. based wafer companies, but foresaw more action to come.
"However, we see possibility for the ban to gradually extend to include restrictions on all solar modules which contain Xinjiang-produced polysilicon," he said.
Chinese module producers could still use polysilicon from Inner Mongolia and Yunnan for their U.S.-bound module shipments, he added.
About 45% of all polysilicon used in solar module production is produced in Xinjiang, with 35% produced in other parts of China. The remainder comes from outside China.
The global solar energy supply chain has been squeezed by record high costs for polysilicon, labour and freight. read more
A second source said the move does not conflict with President Joe Biden's climate goals and support for the domestic solar industry.
The sources said the United States is continuing to investigate allegations of forced labor by Chinese companies who supply polysilicon.
The two sources familiar with the policy said the White House sees the actions as a "natural continuation" of the G7 agreement earlier this month to eliminate forced labor from supply chains.